Indeed, following neoadjuvant chemotherapy for NSCLC, patients who had a higher PD-L1 level after chemotherapy were reported to be chemoresistant as they do not exhibit tumor shrinkage and had shorter survival compared to those with low PD-L1 expression [16]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.